BIOGRAPHICAL SKETCH Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. DO NOT EXCEED FOUR PAGES.

NAME POSITION TITLE MingQiang Ren Assistant Research Scientist. eRA COMMONS USER NAME

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) DEGREE INSTITUTION AND LOCATION YEAR(s) FIELD OF STUDY (if applicable) Dept. of Animal Science, Anhui Agricultural, Bachelor 1980-1984 Animal Science Univ. Hefei, China Institute of Animal Physiology and Biochemistry MS 1984-1987 Animal Physiology in Nanjing Agricultural Univ., Nanjing, China Graduate Institute of Animal Physiology and Biochemistry Animal Physiology and Ph.D. 1996-1999 in Nanjing Agricultural Univ., Nanjing, China Biochemistry Research Institute for the Biology of Animals, Dummerstorf, Germany Postdoctoral 1999-2001 Molecular Physiology Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University, Baltimore, MD Postdoctoral 2001-2003 Molecular Oncology

Positions and Experience

1987-1996 Lecturer, Human and Animal Physiology, and Human Anatomy, Department of Biology, Huaibei Normal College, Huaibei, China. 2003-2006 Research Affiliate, Molecular Oncology, Roswell Park Cancer Institute, Dept. of Cancer Genetics, Buffalo, NY 2006-2009 HRI Scientist, Molecular Oncology, Roswell Park Cancer Institute, Dept. of Cancer Genetics, Buffalo, NY. 2009-date Assistant Research Scientist (faculty position), Department of Pathology, Georgia Health Sciences University, 1120 15th Augusta, GA

Memberships:

2002-date Active member, the American Association for Cancer Research (AACR) 2006-date Active member, the American Society for Cell Biology (ASCB)

Publications

1. Ren M., Sun, Z.P. Endocrinology. In: Animal of Physiology, Chinese Agricultural Publisher, Beijing, p 287-302. 1997 2. Ren, M., Shen, Z.M., Zhao, R.Q., Lu, T.S. and Chen, J. Effects of the novel polyester ionophore hainanmycin on nutrient digestion, metabolism and ruminal characteristics of goats. J.Anim. & Food Sci.7, 21-28. 1998 3. Ren M., Zhao, R.Q. and Chen, J. Effect of ionophore hainanmycin at different concentration on rumen metabolism of goats. J. Nanjing Agri.Univ. 21(3):76-79.1998 4. Ren M. Cell Signalling. In: Modern Biochemistry, Chinese Science & Technology Publisher, Beijing, p 381-410. 1999

5. Xu QF, Sun ZP, Yang JS, Wang JL, Ren M. Studies in vitro on digestibility of crude fiber by microbe in caecum of Romgchan pigs. J. Yangzhou Univ. 2(3) 31-34 1999 6. Xu QF, Chen J, Ren M, Wang ZR, Lu TS. Effect of buffalo saliva on rumen digestion and metabolism in vitro. J. Nanjing Agri.Univ. 24(2): 83-86, 2001 7. Ren M., Kuhn G., Wegner J. and Chen J. A review: Isoflavones, the substances with the myriad of biological and clinical properties. Eur. J. Nutr. 40(4), 135-46. 2001 8. Ren M., Kuhn G., Wegner J., Nürnberg G., Chen J. and Ender K. Feeding daidzein to late pregnant sows influences the estrogen receptor beta and type 1 insulin-like growth factor receptor mRNA expression in newborn piglets. J. Endocrinology. 170, 129-35. 2001 9. Ren M., Wegner J., Bellmann O., Brockmann G., Schneider F., Teuscher F. and Ender K. Comparing mRNA levels of genes related to adipogenesis between dairy and meat cattle. Domest Anim Endocrinol. 23(3):371-81. 2002 10. Wang ZY, Ren M, Xu QF, Zhu Z, Luo QJ and J Chen. Effects of Enveloped Cysteamine on Buffalo Rumen Digestion and Metabolism. J. Xingjiang Agri. Univ. 25(2): 42-47, 2002 11. Wang ZY, Xu QF, Ren M, Luo QJ and J Chen. Effects of cysteamine on goat rumen digestion and metabolism. Grass-feeding livestock, 2002, 4: 42-45. 12. Sirchia SM, Ren M. (co-first author), Pili R, Sironi E, Somenzi G, Ghidoni R, Toma S, Nicolo G, Sacchi N. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res. 62(9):2455-61. 2002. 13. Wang ZY, Ren M, Xu QF, Luo QJ and J Chen. Effects of somatostatin genetic-engineering vaccine on some metabolites and hormones in sheep peripheral blood. Acta veterinaria et zootechnica sinica, 35 (4): 404-408, 2004 14. Shen ZM, Chen, J and Ren M. Effect of pentagastrin on ruminal microbial metabolism in vitro. J. Nanjing Agri.Univ. 27(1): 85-88, 2004 15. Shen ZM, Chen, J and Ren M. Protective effects of hainanmysin on concentration of rumen peptides in goats. J. Nanjing Agri.Univ. 27(4): 73-76, 2004 16. Huff P., Ren M, Lozeman F., Weselake R., and Wegner J. Expression of peroxisome proliferator- activated receptor (PPAR) mRNA in adipose and muscle tissue of two different metabolic types of cattle. Can. J. Anim. 84 (1): 49-55. 2004. 17. Kuhn G, Hennig U, Kalbe C., Rehfeldt C, Ren M, Moors S, Degen GH. Growth performance, carcass characteristics and bioavailability of isoflavones in pigs fed soy bean based diets. Arch Anim Nutr. 58(4):265-76. 2004. 18. Ren M, Reilly RT, Sacchi N. Sasa health exerts a protective effect on Her2/NeuN mammary tumorigenesis. Anticancer Res. 24(5A):2879-84. 2004 19. Qian DZ, Ren M., Wei Y, Wang X, van de Geijn F, Rasmussen C, Nakanishi O, Sacchi N, Pili R. In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells. Prostate. (64): 20-8. 2005 20. Wang X, Qian DZ, Ren M., Kato Y., Wei Y., Zhang L., Fansler Z., Clark D., Nakanishi O., Pili, R. Epigenetic Modulation of Retinoic Acid Receptor 2 by the Histone Deacetylase Inhibitor MS-275 in Human Renal Cell Carcinoma. Clin Cancer Res. 11(9):3535-42. 2005 21. Ren, M, Pozzi, S., Bistulfi G., Somenzi G., Rossetti S. and Sacchi N. Impaired RA-signal Leads to RAR2 Epigenetic Silencing and RA-resistance. Mol. Cell. Biol. 25(23):10591-10603. 2005. 22. Shen XZ, Wang XJ, Ren M and J Chen. Surgical installation of chronic portal, hepatic, mesenteric veins and femoral artery multi-catheters. Chinese J. Comp. Med. 16(4): 236-239, 2006 23. Wang ZY, Xu QF, Ren M, Luo QJ and J Chen. Effects of exogenous cysteamine on hormones and net nutrients across the portal-drained viscera and liver of goat. Acta Veterinaria Et Zootechnica Sinica, 37 (6): 571-579, 2006 24. Bistulfi G., Pozzi, S., Ren, M, Rossetti S. and Sacchi N. A repressive epigenetic domino effect confers susceptibility to breast epithelial cell transformation: implications for predicting breast cancer risk. Cancer Res. 66(21):10308-14, 2006.

25. Somenzi G, Sala G, Rossetti S, Ren M, Ghidoni R, Sacchi N. Disruption of retinoic acid receptor alpha reveals the growth promoter face of retinoic acid. PLoS ONE. 2(9):e836, 2007. 26. Safina A., Ren M, VanDette, E. and Bakin AV. TAK1 is required for TGFbeta-mediated regulation of matrix metalloproteinase-9 and metastasis. Oncogene. 27(9):1198-207, 2008 27. Corlazzoli F., Rossetti S., Bistulfi G., Ren M. and SacchiN. Derangement of a factor upstream of RARα triggers the repression of a pleiotropic epigenetic network. PLoS ONE. 4(1):e4305, 2009 28. Ren M., Li X., Cowell JK. Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198- FGFR1 chimeric tyrosine kinase. Blood. 114(8):1576-84, 2009 29. Teng Y, Ren M, Cheney R, Sharma S, Cowell JK. Inactivation of the WASF3 gene in prostate cancer cells leads to suppression of tumorigenicity and metastases. Br J Cancer. 103(7):1066-75, 2010 30. Rath P, Miller DC, Litofsky NS, Anthony DC, Feng Q, Franklin C, Pei L, Free A, Liu J, Ren M, Kirk MD, Shi H. Isolation and characterization of a population of stem-like progenitor cells from an atypical meningioma. Exp Mol Pathol. 90 (2): 179-188, 2011 31. Ren M. Cowell JK. Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease. Blood. 117 (25):6837-47, 2011 32. Ren M, Qin H, Ren R, Tidwell J, Cowell JK. Src activation plays an important role in lymphomagenesis induced by FGFR1-fusion kinases. Cancer Res. 71(23):7312-22, 2011 33. Mao L, Ding J, Perdue A, Yang L, Zha Y, Ren M, Huang S, Cui H, and Ding H-F. Cyclin E1 is a common target of BMI1 and MYCN and a prognostic marker for neuroblastoma progression. Oncogene, 2011 Nov. [Epub ahead of print] 34. Ren M, Tidwell J, Sharma S, and Cowell JK. Acute progression of BCR-FGFR1 induced murine B- lympho/myeloproliferative disorder suggests involvement of lineages at the pro-B cell stage. PLoS One. 7(6):e38265, 2012 35. Mao L, Ding J, Perdue A, Yang L, Zha Y, Ren M, Huang S, Cui H, and Ding H-F. Cyclin E1 is a common target of BMI1 and MYCN and a prognostic marker for neuroblastoma progression. Oncogene, doi: 10.1038 [Epub ahead of print], 2011 36. McCarthy BA, Yang L, Ding J, Ren M, King W, Elsalanty M, Zakhary I, Sharawy M, Cui H, Ding HF. NF-kappaB2 mutation targets survival, proliferation and differentiation pathways in the pathogenesis of plasma cell tumors. BMC Cancer.12(1):203. [Epub ahead of print], 2012 37. Ren M, Qin H, Ren R, Tidwell J, Cowell JK. Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities. Leukemia (accepted), 2012

Research Support

Ongoing

Title: Genetic analysis of myeloproliferative disease R01 CA076167 Goal: The specific aims of this proposal are to create and analyze mouse models of AMPD by retroviral transduction of mouse bone marrow cell and determine whether genetic events seen in model systems also occur in hematopoietic cells from AMPD. Time Commitment: Co-Investigator Supporting Agency: NCI (National Cancer Institute) Duration: 04/01/1999 – 07/31/2012 Pending

Title: Up-regulation of Notch1 as a targeted therapeutic approach for AML Goal: To study the mechanism under which Notch1 signaling functions as a tumorsuppressor and also to test whether genetic or pharmacological activation of Notch1signaling pathway can inhibit leukemogenesis in AML. Time Commitment: Principal Investigator (40%) Supporting Agency: DOD

DOD FY11 Peer Reviewed Cancer Discovery Award Rockville, MD Performance Period: 09/30/2012 – 09/29/2014

Title: Preclinical trial of drug regimens in a model of human SCLL syndrome Goal: To use humanized mouse models to test whether targeting FGFR1 kinase in combination with BCL2 and NOTCH1 inhibitors will prevent mice from developing leukemia and lymphoma induced by different chimeric FGFR1 fusion genes. Time Commitment: Principal Investigator (10%) Supporting Agency: The Georgia Cancer Coalition Performance Period: 05/01/2012 – 04/31/2013